Alterity Therapeutics Files 6-K, Incorporates into Registration Statements
Ticker: PRNAF · Form: 6-K · Filed: Aug 22, 2025 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Aug 22, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: registration-statement, filing-update, securities-application
Related Tickers: ATH
TL;DR
Alterity Therapeutics (ATH) filed a 6-K on 8/22/25, incorporating into existing S-8/F-3 filings. Exhibit 99.1 is an application for quotation.
AI Summary
Alterity Therapeutics Ltd. filed a Form 6-K on August 22, 2025, to incorporate by reference into several of its existing Registration Statements on Form S-8 and Form F-3. The filing includes an exhibit (99.1) related to an application for quotation of securities under the ticker ATH.
Why It Matters
This filing indicates ongoing administrative and regulatory activities for Alterity Therapeutics, potentially related to stock offerings or employee stock plans, which are important for investors tracking the company's corporate actions.
Risk Assessment
Risk Level: low — This is a routine administrative filing that incorporates previous documents into registration statements and does not introduce new material financial or operational information.
Key Players & Entities
- Alterity Therapeutics Ltd. (company) — Registrant
- ATH (company) — Ticker symbol for Alterity Therapeutics
- August 22, 2025 (date) — Filing date
- Form S-8 (document) — Registration Statement type
- Form F-3 (document) — Registration Statement type
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is being incorporated by reference into Alterity Therapeutics' existing Registration Statements on Form S-8 and Form F-3.
What exhibit is included with this filing?
Exhibit 99.1, an application for quotation of securities (ATH), is submitted with this Form 6-K.
What is the filing date of this Form 6-K?
The filing date of this Form 6-K is August 22, 2025.
What are the registration statements mentioned in the filing?
The filing mentions Registration Statements on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076).
What is the principal executive office address of Alterity Therapeutics?
The principal executive office is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Filing Stats: 191 words · 1 min read · ~1 pages · Grade level 12 · Accepted 2025-08-22 06:55:17
Filing Documents
- ea0254306-6k_alterity.htm (6-K) — 14KB
- ea025430601ex99-1_alterity.htm (EX-99.1) — 42KB
- ex99-1_001.jpg (GRAPHIC) — 1KB
- 0001213900-25-079556.txt ( ) — 59KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Application for quotation of securities - ATH 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: August 22, 2025 2